Anaptysbio Inc (ANAB)

$57.68 +0.95 (1.67%)
Market Cap 1.66B
Revenue (ttm) 234.60M
Net Income (ttm) -13.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.64%
Debt to Equity Ratio 0.00
Volume 611,600
Avg Vol 553,214
Day's Range N/A - N/A
Shares Out 28.75M
Stochastic %K 27%
Beta 0.40
Analysts Strong Sell
Price Target $80.58

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 362 6295
Address:
10770 Wateridge Circle, Suite 210, San Diego, United States
WAJeff
WAJeff Apr. 1 at 8:52 PM
$ANAB Looked at this last July when it was in the 26s. Now 56s, missed a huge move here sadly.
1 · Reply
StockBraker
StockBraker Apr. 1 at 3:00 PM
$ANAB Company will be splitting into 2 in just 10 days. Prospects for each standalone company are quite good. Personally, looking for a combined share price of $75 in the next 3-4 months.
1 · Reply
Quantumup
Quantumup Mar. 31 at 2:12 PM
Piper Sandler⬆️ $ANAB to $95/reitd Overweight. $GSK XBI FBRX ENTO TAK TEVA SNY AZN - AMGN BMY $EPRX PHAT Piper Sandler said in its note: ANAB has traded up ~190%+ (vs ~45%+ XBI) over the last year largely driven by the success of JEMPERLI's launch (partnered with GSK, not covered) and ANB033's (CD122 antagonist) opportunity in Celiac disease (CeD) and eosinophilic esophagitis (EoE). Hence, ahead of ANB033 Ph1b data in CeD (4Q26) and EoE (mid-2027), we answered 34 investor questions related to its mechanistic rationale in inflammatory disease, pre-clinical and clinical data, expectations ahead of data readouts, competitive landscape, and the regulatory path in both indications. Importantly, it is crucial to appreciate both indications represent blockbuster opportunities where nothing is approved in CeD and EoE has high remaining unmet need. Thus, we remain bullish on ANAB and believe ANB033 represents a significant value proposition. We updated our model, raising our PT to $95 (from $67).
0 · Reply
StockBraker
StockBraker Mar. 30 at 6:20 PM
$ANAB Buying
0 · Reply
PickAlpha
PickAlpha Mar. 28 at 4:34 PM
2/3: AnaptysBio approved a First Tracks spin-off, priced a $145.00 mn private placement at $13.81/share, and authorized a $100.00 mn buyback | View: Spin-off plus funded First Tracks entity and a sizable $100 million ANAB buyback authorization… $ANAB $XBI
0 · Reply
StockBraker
StockBraker Mar. 28 at 11:37 AM
$ANAB is spinning off its clinical-stage biopharma pipeline and operations into a new independent public company called First Tracks Biotherapeutics (NASDAQ: TRAX, expected to begin regular-way trading on April 20, 2026). The remaining company will retain the AnaptysBio name and ticker (ANAB) as a lean, high-margin royalty management business focused primarily on its Jemperli (dostarlimab) royalties from GSK, plus imsidolimab royalties/milestones from Vanda. AnaptysBio shareholders of record as of April 6, 2026, will receive one share of TRAX for every one share of ANAB they own (pro-rata dividend). This is a tax-free spin-off in most cases
0 · Reply
StockBraker
StockBraker Mar. 27 at 4:19 PM
$ANAB
0 · Reply
StockBraker
StockBraker Mar. 27 at 4:16 PM
$ANAB Drops makes no sense to me, but "What me worry?" https://finance.yahoo.com/sectors/healthcare/articles/first-tracks-biotherapeutics-planned-spin-130000297.html
0 · Reply
hbwalk2
hbwalk2 Mar. 27 at 3:56 PM
$ANAB arbitrage trading. shorting shs before spin-off
0 · Reply
WhaleAndState
WhaleAndState Mar. 27 at 1:25 PM
$ANAB market cap at $1.9B — stock down 0.61% post-announcement. Filing states "March 26, 2026" as the date of the earliest event reported. The market reacts to the long-term timeline, indicating skepticism on execution.
0 · Reply
Latest News on ANAB
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Mar 27, 2026, 9:00 AM EDT - 9 days ago

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Mar 27, 2026, 9:00 AM EDT - 9 days ago

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Mar 27, 2026, 9:00 AM EDT - 9 days ago

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 11:20 AM EDT - 26 days ago

AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Feb 25, 2026, 7:18 AM EST - 5 weeks ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

Anaptys Announces Participation at Upcoming Investor Conferences

Feb 5, 2026, 4:15 PM EST - 2 months ago

Anaptys Announces Participation at Upcoming Investor Conferences

AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 11:25 PM EST - 2 months ago

AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Jan 8, 2026, 7:09 PM EST - 3 months ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

GSK

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Jan 8, 2026, 6:00 PM EST - 3 months ago

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:15 PM EST - 3 months ago

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Dec 15, 2025, 7:00 AM EST - 3 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

Anaptys Announces Participation in December Investor Conferences

Nov 25, 2025, 4:15 PM EST - 4 months ago

Anaptys Announces Participation in December Investor Conferences

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Nov 21, 2025, 8:52 AM EST - 4 months ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

GSK

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

Nov 21, 2025, 8:48 AM EST - 4 months ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

Nov 21, 2025, 6:14 AM EST - 4 months ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

GSK

Anaptys Announces $100 Million Stock Repurchase Plan

Nov 21, 2025, 4:00 AM EST - 4 months ago

Anaptys Announces $100 Million Stock Repurchase Plan

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

Nov 21, 2025, 3:50 AM EST - 4 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GSK

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Nov 13, 2025, 7:30 AM EST - 5 months ago

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

Nov 10, 2025, 12:30 PM EST - 5 months ago

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Nov 10, 2025, 9:00 AM EST - 5 months ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:15 PM EST - 5 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in November Investor Conferences

Nov 4, 2025, 4:15 PM EST - 5 months ago

Anaptys Announces Participation in November Investor Conferences

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Oct 29, 2025, 9:15 AM EDT - 5 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

AnaptysBio, Inc. - Special Call

Oct 15, 2025, 5:37 AM EDT - 6 months ago

AnaptysBio, Inc. - Special Call

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Oct 13, 2025, 9:15 AM EDT - 6 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Sep 30, 2025, 1:59 PM EDT - 6 months ago

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 6 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Sep 29, 2025, 4:05 PM EDT - 6 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Anaptys Announces Participation in September Investor Conferences

Aug 27, 2025, 4:15 PM EDT - 7 months ago

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:15 PM EDT - 8 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Jun 10, 2025, 1:33 PM EDT - 10 months ago

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

Jun 6, 2025, 3:39 PM EDT - 10 months ago

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Jun 4, 2025, 2:23 PM EDT - 10 months ago

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Jun 3, 2025, 4:05 PM EDT - 10 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 27, 2025, 4:15 PM EDT - 11 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:15 PM EDT - 11 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Stock Repurchase Plan

Mar 24, 2025, 9:15 AM EDT - 1 year ago

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Participation in March Investor Conferences

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 11, 2025, 5:30 PM EST - 1 year ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 4:15 PM EST - 1 year ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Feb 3, 2025, 7:30 AM EST - 1 year ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 9:15 AM EST - 1 year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 2:07 PM EST - 1 year ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 10:20 AM EST - 1 year ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 1 year ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

WAJeff
WAJeff Apr. 1 at 8:52 PM
$ANAB Looked at this last July when it was in the 26s. Now 56s, missed a huge move here sadly.
1 · Reply
StockBraker
StockBraker Apr. 1 at 3:00 PM
$ANAB Company will be splitting into 2 in just 10 days. Prospects for each standalone company are quite good. Personally, looking for a combined share price of $75 in the next 3-4 months.
1 · Reply
Quantumup
Quantumup Mar. 31 at 2:12 PM
Piper Sandler⬆️ $ANAB to $95/reitd Overweight. $GSK XBI FBRX ENTO TAK TEVA SNY AZN - AMGN BMY $EPRX PHAT Piper Sandler said in its note: ANAB has traded up ~190%+ (vs ~45%+ XBI) over the last year largely driven by the success of JEMPERLI's launch (partnered with GSK, not covered) and ANB033's (CD122 antagonist) opportunity in Celiac disease (CeD) and eosinophilic esophagitis (EoE). Hence, ahead of ANB033 Ph1b data in CeD (4Q26) and EoE (mid-2027), we answered 34 investor questions related to its mechanistic rationale in inflammatory disease, pre-clinical and clinical data, expectations ahead of data readouts, competitive landscape, and the regulatory path in both indications. Importantly, it is crucial to appreciate both indications represent blockbuster opportunities where nothing is approved in CeD and EoE has high remaining unmet need. Thus, we remain bullish on ANAB and believe ANB033 represents a significant value proposition. We updated our model, raising our PT to $95 (from $67).
0 · Reply
StockBraker
StockBraker Mar. 30 at 6:20 PM
$ANAB Buying
0 · Reply
PickAlpha
PickAlpha Mar. 28 at 4:34 PM
2/3: AnaptysBio approved a First Tracks spin-off, priced a $145.00 mn private placement at $13.81/share, and authorized a $100.00 mn buyback | View: Spin-off plus funded First Tracks entity and a sizable $100 million ANAB buyback authorization… $ANAB $XBI
0 · Reply
StockBraker
StockBraker Mar. 28 at 11:37 AM
$ANAB is spinning off its clinical-stage biopharma pipeline and operations into a new independent public company called First Tracks Biotherapeutics (NASDAQ: TRAX, expected to begin regular-way trading on April 20, 2026). The remaining company will retain the AnaptysBio name and ticker (ANAB) as a lean, high-margin royalty management business focused primarily on its Jemperli (dostarlimab) royalties from GSK, plus imsidolimab royalties/milestones from Vanda. AnaptysBio shareholders of record as of April 6, 2026, will receive one share of TRAX for every one share of ANAB they own (pro-rata dividend). This is a tax-free spin-off in most cases
0 · Reply
StockBraker
StockBraker Mar. 27 at 4:19 PM
$ANAB
0 · Reply
StockBraker
StockBraker Mar. 27 at 4:16 PM
$ANAB Drops makes no sense to me, but "What me worry?" https://finance.yahoo.com/sectors/healthcare/articles/first-tracks-biotherapeutics-planned-spin-130000297.html
0 · Reply
hbwalk2
hbwalk2 Mar. 27 at 3:56 PM
$ANAB arbitrage trading. shorting shs before spin-off
0 · Reply
WhaleAndState
WhaleAndState Mar. 27 at 1:25 PM
$ANAB market cap at $1.9B — stock down 0.61% post-announcement. Filing states "March 26, 2026" as the date of the earliest event reported. The market reacts to the long-term timeline, indicating skepticism on execution.
0 · Reply
StockBraker
StockBraker Mar. 27 at 1:21 PM
$ANAB AnaptysBio announces that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company''s outstanding common stock, par value $0.001 per share, and provided a business update Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026. Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investments. Susannah Gray, former CFO of Royalty Pharma, appointed to Anaptys'' Board of Directors.
1 · Reply
TalkMarkets
TalkMarkets Mar. 25 at 2:00 PM
AnaptysBio Inc: Chart Analysis $ANAB https://talkmarkets.com/article/anaptysbio-inc-chart-analysis-1774447224
0 · Reply
StockBraker
StockBraker Mar. 23 at 10:16 PM
$ADMA $ANAB $STRL - While ADMA is not a top ten holding of the Investor Business Daily ETF holdings ($FFTY) it is one of about 50 stocks included.
1 · Reply
Mungermind
Mungermind Mar. 22 at 10:28 PM
$IMMX Anyone remember how anaptsys bio ($ANAB ) has rose starting when Millennium / Israel Englander announced their 5.1% stake in the company at the end of September 2025? Hoping he is smarter than all of us and sees high potential for NXC 201
2 · Reply
hbwalk2
hbwalk2 Mar. 20 at 4:14 PM
$ANAB someone paid $3 for $70 call expiring today???
0 · Reply
hbwalk2
hbwalk2 Mar. 20 at 3:47 PM
$ANAB big volume. Op Ex meaningless. Looks like a few 100k shs trading off exchange. Any thoughts ?
1 · Reply
StockBraker
StockBraker Mar. 18 at 3:59 PM
$ANAB
0 · Reply
StockBraker
StockBraker Mar. 17 at 8:31 PM
$ANAB Beauty 🤩
0 · Reply
STACKD0E
STACKD0E Mar. 16 at 12:42 PM
$ANAB 🙃✨️
0 · Reply
StockBraker
StockBraker Mar. 13 at 2:00 PM
$ANAB
0 · Reply
erevnon
erevnon Mar. 12 at 5:38 PM
Wedbush maintains AnaptysBio $ANAB at Outperform and raises the price target from $60 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
StockBraker
StockBraker Mar. 11 at 4:17 PM
$ANAB MarketBear article posted here on ST.
1 · Reply